
Assist. Prof. Lymphoma @MDAndersonNews via @GACancerCenter | @LombardiCancer | @Uconn
Houston, TX
Joined October 2019
- Tweets435
- Following704
- Followers690
- Likes8.9K
Brilliant work! We have been using this modified regimen in practice for sometime so good to see published efficacy data.
A modified MTX-rituximab-temozolomide regimen achieved a 77% complete response rate in patients with newly diagnosed PCNSL. The MTX-rituximab-temozolomide regimen was well tolerated and yielded a 72% 2-year PFS rate in patients aged ≥70 years. ow.ly/yFVz5102Elp
Ayushi Chauhan retweeted
A low ANC isn’t always pathological! ASH’s work reinforces the need for ancestry-aware reference ranges to avoid unnecessary investigations and treatment interruptions.
Indian takeaway: With our genetic diversity, we need locally validated ANC reference ranges NOT a one-size-fits-all approach based on Western cutoffs.
ASH has established new reference ranges for individuals with Duffy-null status, helping clinicians interpret blood counts more accurately and reduce unnecessary testing and treatment interruptions. ow.ly/b3Zm5104hvh
Ayushi Chauhan retweeted
Bispecific activity in the CNS is no longer anecdotal. Glofitamab-based (investigational in CNS), R/R CNS lymphoma, retrospective, 84 pts: CR 59-81% PCNSL, 65-75% SCNSL; mPFS 19.5 vs 13.5 mo; CRS 40% (G1-2), ICANS 8%. @BCD_AACR #lymsm #PCNSL doi.org/10.1158/2643-3230.BC…
Ayushi Chauhan retweeted
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
Ayushi Chauhan retweeted
Just published in @BloodJournal our @FredHutch investigator-initiated trial of CD20 CAR T in Waldenström macroglobulinemia—the largest reported CAR T series in WM.
Developed in Brian Till’s lab; I had the privilege of serving as PI.
The joy of bringing science from lab to clinic!
ashpublications.org/blood/ar……
@IWMF_WM
Ayushi Chauhan retweeted
Don't miss this session at ASH on CAR sequencing and emerging platforms with Dr's Nasta and @niravshahmd – at Bellaire, TX
X
CAR-T sequencing and emerging cell therapy platforms: how will you decide? Join me, Drs. Ahmed (@drsairahahmed) and Nasta on Fri 12/11 at 7:00 PM CST, for a @PeerView and @HealthTree symposium during #ASH26: bit.ly/2026-CART-T
Ayushi Chauhan retweeted
X
CAR-T sequencing and emerging cell therapy platforms: how will you decide? Join me, Drs. Ahmed (@drsairahahmed) and Nasta on Fri 12/11 at 7:00 PM CST, for a @PeerView and @HealthTree symposium during #ASH26: bit.ly/2026-CART-T
Ayushi Chauhan retweeted
1/12 Excited to share our new study, out today in @NatureGenet on clonal hematopoiesis (CH) & cytopenias after CAR19 therapy. Led by Mark Hamilton and team with David Miklos and @max_diehn. How do blood-cell clones evolve after CAR T vs conventional cytotoxic Rx?
Ayushi Chauhan retweeted
Just published in @BloodAdvances!
"CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States"
Only ~15% of patients receive CAR T.
We need to continue generating data, raising awareness, and improving access and utilization.
ashpublications.org/bloodadv…
Thanks to all the authors and collaborators at @bmsnews
@lymphomaphilia @KrishPatelMD @LNastoupilMD @mana1981
Ayushi Chauhan retweeted
Another score for BsAb: CAR-HEMATOTOX, a score built for CAR-T, applied retrospectively to odronextamab (CD20xCD3) in heavily pretreated B-cell non-Hodgkin #lymphoma across ELM-1 and ELM-2.
High scores had numerically higher grade >=2 CRS within 30 days, and higher grade >=3 infection.
PFS in #DLBCL 2.6 vs 9.6 months (P<0.0001).
I see this and our previously described score for glofit and others (pmc.ncbi.nlm.nih.gov/article…) as not management-changing, but rather a guide to which disease features drive toxicity (and maybe treatment failure) and, therefore, who to watch more closely in practice.
#DLBCL #lymphoma
#lymsm
doi.org/10.1111/bjh.70869
Ayushi Chauhan retweeted
#Glofitamab with #polatuzumab vedotin in relapsed/refractory CNS #lymphoma: retrospective single-institution series, n=9, including chemorefractory Burkitt #lymphoma and TP53-mutant mantle cell #lymphoma.
ORR 100%, CR 89%. Responses in both brain parenchymal and leptomeningeal disease, with flow cytometry showing clearance of #lymphoma cells from CSF within days of treatment.
n=9, retrospective, short follow-up... so this is a signal rather than proof but enough to justify more evaluation in trials.
#CNSL #lymphoma
#lymsm
doi.org/10.1182/bloodadvance…
Ayushi Chauhan retweeted
The Lymphoma Research Foundation exists as a safe, trusted place for patients, survivors and their families for every step of the journey.
Support the millions of Americans affected by this disease by donating today: bit.ly/4y0xe5s
Ayushi Chauhan retweeted
Very interesting and pertains to myeloma even more.
Dr. Mark Rocschewski @MSKCancerCenter presenting at @eaonc Heme Malignancy session showed this interesting slide pertaining to large cell lymphoma.
Patients who clear circulating tumor DNA of course do well. But what’s interesting is 25% of patients with detectable circulating tumor DNA have no recurrence. A real plateau!
Residual ctDNA (or MRD) may not necessarily mean bad outcome.
Ayushi Chauhan retweeted
Thanks to @Capt__Kirkwood for highlighting this study of accelerated step-up glofitamab including n=19 patients with CNSL (10 PCNSL, 9 SCNSL). No rates of Gr3+ ICANS seen, different from previous retrospective data where ICANS has been a concern...
doi.org/10.1002/hon.70270
Ayushi Chauhan retweeted
Accelerated #glofitamab bridging to CAR-T in high-risk R/R #lymphoma (n=41): day-12 ORR 80.5%; 92.7% reached CAR-T; CRS 19.5%. Not the first rapid ramp we've seen – easier with IV BsAb PK than SC, where a wider variation of CRS timing is possible. #lymsm doi.org/10.1002/hon.70270
Ayushi Chauhan retweeted
Honored to be elected to the @NAMedicine! Grateful to the many talented colleagues and team members I’ve had the privilege of working with over the years. Especially delighted to share this recognition with @ACKoongMDPhD
Congratulations to Drs. Albert Koong and Katy Rezvani for being elected to @theNAMedicine, one of the nation’s most prestigious organizations in health and science.
Read more about their contributions to cancer care and research. @lab_rezvani @ACKoongMDPhD #EndCancer spr.ly/6010BHRAJI
Ayushi Chauhan retweeted
Thanks to Dr. Martin's leadership as chair of the Foundation’s Mantle Cell Lymphoma Consortium, the field has seen significant breakthroughs in MCL treatment.
Join us as we honor him with the Distinguished Leadership Award: lymphoma.org/gala
Great time at 2026 Nashville Hematology Summit organized by @binaytara. Had the opportunity to debate FOR bispecifics in r/r DLBCL: can’t get A (access!) to C (cancer control/cost effective care/CAR-T) without B (easily accessible, ❓durable, bridging BITEs!!) @UTMDAnderson
We join the oncology community in mourning the passing of Dr. Rachna T. Shroff, a renowned GI cancers expert and a dedicated ASCO volunteer. We are humbled by her dedication and strive to honor her legacy of commitment and altruism.
Read more: bit.ly/4e7jBKu
Ayushi Chauhan retweeted
👉We deeply mourn the loss of our dear friend, loving big sister, co-fellow, world expert, the brilliant light, amazing all-time Dr .@rachnatshroff | May she rest in peace. May her wonderful legacy carry on forever, may we never forget @rachnatshroff 🙏
medicine.arizona.edu/news/20…





























